Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Verastem Inc Receives Orphan Drug Designation from U.S. FDA For Defactinib In Mesothelioma


Wednesday, 24 Jul 2013 07:00am EDT 

Verastem, Inc. announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of mesothelioma, a rare form of lung cancer. The designation is designed to encourage the development of drugs which may provide benefit to patients suffering from rare diseases. 

Company Quote

8.57
-0.89 -9.41%
2:37pm EDT